Review and prospect of clinical application of umbilical cord blood transplantation for 30 years
-
摘要: 造血干细胞移植是治愈血液系统恶性肿瘤、造血衰竭性疾病和先天性遗传性代谢性疾病的重要方法。脐血是造血干细胞的主要来源之一,是干细胞研究及应用最理想的细胞来源。本文从脐血移植的历史及现状、脐血移植的优势、脐血移植技术的改进、脐血移植的应用前景及展望等方面,对脐血移植30多年的临床应用进行回顾和展望。Abstract: Hematopoietic stem cell transplantation is a pivotal method to treat hematological malignancies, hematopoietic failure diseases and inherited metabolic diseases. Umbilical cord blood is one of the main sources of hematopoietic stem cells and the most ideal cell source for stem cell research and application. In this article, the clinical application of umbilical cord blood transplantation for more than 30 years was reviewed from the aspects of the history, current situation, advantages, improvement, application prospect and expectation of umbilical cord blood transplantation.
-
[1] GABELLI M, VEYS P, CHIESA R. Current status of umbilical cord blood transplantation in children[J]. Br J Haematol, 2019, DOI: 10.1111/bjh.16107[Epubahead of print]. [2] 孙自敏, 汤宝林.我如何用单份脐血干细胞移植治疗成人恶性血液病[J].中华血液学杂志, 2019, 40(6): 449-452. DOI: 10.3760/cma.j.issn.0253-2727.2019.06.001.SUN ZM, TANG BL. How I treat adult malignant hematological diseases with single umbilical cord blood transplantation[J]. Chin J Hematol, 2019, 40(6): 449-452. DOI: 10.3760/cma.j.issn.0253-2727.2019.06.001. [3] WAGNER JE, BROXMEYER HE, BYRD RL, et al. Transplantation of umbilical cord blood after myeloablative therapy: analysis of engraftment[J]. Blood, 1992, 79(7):1874-1881. doi: 10.1182/blood.V79.7.1874.1874 [4] KURTZBERG J, LAUGHLIN M, GRAHAM ML, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients[J]. N Engl J Med, 1996, 335(3):157-166. doi: 10.1056/NEJM199607183350303 [5] WAGNER JE, ROSENTHAL J, SWEETMAN R, et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease[J]. Blood, 1996, 88(3):795-802. doi: 10.1182/blood.V88.3.795.795 [6] ROCHA V, WAGNER JE JR, SOBOCINSKI KA, et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling[J]. N Engl J Med, 2000, 342(25):1846-1854. doi: 10.1056/NEJM200006223422501 [7] WAGNER JE, GLUCKMAN E. Umbilical cord blood transplantation: the first 20 years[J]. Semin Hematol, 2010, 47(1):3-12. DOI: 10.1053/j.seminhematol.2009.10.011. [8] KÖGLER G, SENSKEN S, AIREY JA, et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential[J]. J Exp Med, 2004, 200(2):123-135. doi: 10.1084/jem.20040440 [9] FATOBENE G, STORER BE, SALIT RB, et al. Disability related to chronic graft -versus-host disease after alternative donor hematopoietic cell transplantation[J]. Haematologica, 2019, 104(4):835-843. DOI: 10.3324/haematol.2018.202754. [10] PASCAL L, TUCUNDUVA L, RUGGERI A, et al. Impact of ATG-containing reduced-intensity conditioning after single- or double-unit allogeneic cord blood transplantation[J]. Blood, 2015, 126(8):1027-1032. DOI: 10.1182/blood-2014-09-599241. [11] TONG J, XUAN L, SUN Y, et al. Umbilical cord blood transplantation without antithymocyte globulin results in similar survival but better quality of life compared with unrelated peripheral blood stem cell transplantation for the treatment of acute leukemia-a retrospective study in China[J]. Biol Blood Marrow Transplant, 2017, 23(9):1541-1548. DOI: 10.1016/j.bbmt.2017.05.004. [12] SARVARIA A, BASAR R, MEHTA RS, et al. IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation[J]. Blood, 2016, 128(10):1346-1361. DOI: 10.1182/blood- 2016-01-695122. [13] HIWARKAR P, QASIM W, RICCIARDELLI I, et al. Cord blood T cells mediate enhanced antitumor effects compared with adult peripheral blood T cells[J]. Blood, 2015, 126(26):2882-2891. DOI: 10.1182/blood- 2015-06-654780. [14] MILANO F, APPELBAUM FR, DELANEY C. Cord-blood transplantation in patients with minimal residual disease[J]. N Engl J Med, 2016, 375(22):2204-2205. http://www.ncbi.nlm.nih.gov/pubmed/27602666 [15] SUN Z, LIU H, LUO C, et al. Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: a retrospective (development) and a prospective (validation) study[J]. Int J Cancer, 2018, 143(3):699-708. DOI: 10.1002/ijc.31339. [16] TANG B, ZHU X, ZHENG C, et al. Retrospective cohort study comparing the outcomes of intravenous busulfan vs. total-body irradiation after single cord blood transplantation[J]. Bone Marrow Transplant, 2019, 54(10):1614-1624. DOI: 10.1038/s41409-019-0441-4. [17] WU Y, LI Y, FU B, et al. Programmed differentiated natural killer cells kill leukemia cells by engaging SLAM family receptors[J]. Oncotarget, 2017, 8(34):57024-57038. DOI: 10.18632/oncotarget.18659. [18] DELANEY C, HEIMFELD S, BRASHEM-STEIN C, et al. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution[J]. Nat Med, 2010, 16(2):232-236. DOI: 10.1038/nm.2080.
点击查看大图
计量
- 文章访问数: 267
- HTML全文浏览量: 83
- PDF下载量: 26
- 被引次数: 0